The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases

• Published in: International immunopharmacology 2022-01, Vol.102, p.108402-108402, Article 108402
• Main Authors: Berry, S.P. Déo-Gracias, Dossou, Camille, Kashif, Ali, Sharifinejad, Niusha, Azizi, Gholamreza, Hamedifar, Haleh, Sabzvari, Araz, Zian, Zeineb
• Format: Article
• Language: English
• Subjects: Allergies; Animals; Arthritis; Autoimmune diseases; Autoimmune Diseases - drug therapy; Autoimmune Diseases - immunology; Brodalumab; CD8 antigen; Chronic conditions; Cytokines; Humans; Immunopathogenesis; Inflammation - drug therapy; Inflammation - immunology; Inflammatory diseases; Innate immunity; Interleukin 17; Interleukin-17 - antagonists & inhibitors; Interleukin-17 - metabolism; Interleukin-17 - physiology; Ixekizumab; Lymphocytes; Lymphocytes T; Lymphoid cells; Malignancy; Monoclonal antibodies; Monoclonal antibody; Multiple sclerosis; Natural killer cells; Pathogenesis; Psoriasis; Rheumatoid arthritis; Secukinumab; Skin diseases; Systemic lupus erythematosus
• ISSN: 1567-5769; 1878-1705
• DOI: 10.1016/j.intimp.2021.108402

•Interleukin-17 is a proinflammatory cytokine involved in chronic inflammation.•Interleukin-17 is involved in the pathogenesis of various immune-mediated diseases.•Several IL-17 and IL-17R inhibitors were approved to treat some immune-mediated diseases.•Ixekizumab, Secukinumab, and Brodalumab monoclonal antibodies target IL-17A and IL-17R.•Ixekizumab, Secukinumab, and Brodalumab are extremely effective to treat Psoriasis. Interleukin-17 (IL-17) is a proinflammatory cytokine involved in chronic inflammation occurring during the pathogenesis of allergy, malignancy, and autoimmune diseases such as rheumatoid arthritis, systemic lupus erythematosus, multiple sclerosis, and psoriasis. IL-17 is produced by multiple cell types of adaptive and innate immunity, including T helper 17 cells, CD8 + T cells, γδ T cells, natural killer T cells, and innate lymphoid cells. Monoclonal antibodies (mAbs) targeting IL-17 and/or IL-17R would be a potential approach to study this therapeutic tool for these diseases. In the current review, we aimed to highlight the characteristics of IL-17 and its important role in the pathogenesis of related diseases. Critical evaluation of the mAbs targeting IL-17A and IL-17 receptors (e.g., Ixekizumab, Secukinumab, and Brodalumab) in various immune-mediated diseases will be provided, and finally, their clinical efficacy and safety will be reported.